Wafik S. El‐Deiry

87.5k total citations · 14 hit papers
584 papers, 46.9k citations indexed

About

Wafik S. El‐Deiry is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Wafik S. El‐Deiry has authored 584 papers receiving a total of 46.9k indexed citations (citations by other indexed papers that have themselves been cited), including 371 papers in Oncology, 349 papers in Molecular Biology and 139 papers in Cancer Research. Recurrent topics in Wafik S. El‐Deiry's work include Cancer-related Molecular Pathways (205 papers), Cell death mechanisms and regulation (126 papers) and Cancer Research and Treatments (86 papers). Wafik S. El‐Deiry is often cited by papers focused on Cancer-related Molecular Pathways (205 papers), Cell death mechanisms and regulation (126 papers) and Cancer Research and Treatments (86 papers). Wafik S. El‐Deiry collaborates with scholars based in United States, India and France. Wafik S. El‐Deiry's co-authors include Victor E. Velculescu, Benedito A. Carneiro, K W Kinzler, Takashi Tokino, Zhaoyu Jin, David Pei‐Cheng Lin, Daniel B. Levy, Bert Vogelstein, W E Mercer and J.M. Trent and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Wafik S. El‐Deiry

545 papers receiving 46.1k citations

Hit Papers

WAF1, a potential mediator of p53 tumor suppression 1992 2026 2003 2014 1993 1992 2020 1994 1992 2.0k 4.0k 6.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. WAF1, a potential mediator of p53 tumor suppression
    1993 7.2k citations Wafik S. El‐Deiry et al. profile →
  2. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
    1992 2.7k citations Wafik S. El‐Deiry et al. profile →
  3. Targeting apoptosis in cancer therapy
    2020 1.8k citations Benedito A. Carneiro, Wafik S. El‐Deiry profile →
  4. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.
    1994 1.8k citations Wafik S. El‐Deiry et al. profile →
  5. Definition of a consensus binding site for p53
    1992 1.7k citations Wafik S. El‐Deiry et al. profile →
  6. Overview of cell death signaling pathways
    2005 1.1k citations Wafik S. El‐Deiry et al. profile →
  7. FADD: Essential for Embryo Development and Signaling from Some, But Not All, Inducers of Apoptosis
    1998 759 citations Wafik S. El‐Deiry et al. profile →
  8. TRAIL and apoptosis induction by TNF-family death receptors
    2003 725 citations Wafik S. El‐Deiry et al. profile →
  9. Regulation ofp53downstream genes
    1998 672 citations Wafik S. El‐Deiry profile →
  10. Acoustic separation of circulating tumor cells
    2015 635 citations Lanlan Zhou, Wafik S. El‐Deiry et al. profile →
  11. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death
    2005 598 citations Wafik S. El‐Deiry et al. profile →
  12. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues.
    1995 525 citations Wafik S. El‐Deiry et al. profile →
  13. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
    2021 434 citations Wafik S. El‐Deiry et al. profile →
  14. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.
    1994 358 citations Wafik S. El‐Deiry et al. profile →

Peers

Wafik S. El‐Deiry
Karen H. Vousden United Kingdom
Moshe Oren Israel
David P. Lane United Kingdom
Scott W. Lowe United States
Michael B. Kastan United States
Kornélia Polyák United States
William C. Hahn United States
Victor E. Velculescu United States
David A. Tuveson United States
Albert J. Fornace United States
Karen H. Vousden United Kingdom
Wafik S. El‐Deiry
Citations per year, relative to Wafik S. El‐Deiry Wafik S. El‐Deiry (= 1×) peers Karen H. Vousden

Countries citing papers authored by Wafik S. El‐Deiry

Since Specialization
Citations

This map shows the geographic impact of Wafik S. El‐Deiry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wafik S. El‐Deiry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wafik S. El‐Deiry more than expected).

Fields of papers citing papers by Wafik S. El‐Deiry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wafik S. El‐Deiry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wafik S. El‐Deiry. The network helps show where Wafik S. El‐Deiry may publish in the future.

Co-authorship network of co-authors of Wafik S. El‐Deiry

This figure shows the co-authorship network connecting the top 25 collaborators of Wafik S. El‐Deiry. A scholar is included among the top collaborators of Wafik S. El‐Deiry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wafik S. El‐Deiry. Wafik S. El‐Deiry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ferrarini, Isacco, Anna D. Louie, Lanlan Zhou, & Wafik S. El‐Deiry. (2021). ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer. Molecular Cancer Therapeutics. 20(9). 1572–1583. 28 indexed citations
2.
Baca, Yasmine, Joanne Xiu, Fábio Távora, et al.. (2020). The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer. Molecular Cancer Therapeutics. 20(1). 183–190. 12 indexed citations
3.
Ellithi, Moataz, et al.. (2020). Differential Effects of Clinically Relevant N- versus C-Terminal Truncating CDKN1A Mutations on Cisplatin Sensitivity in Bladder Cancer. Molecular Cancer Research. 19(3). 403–413. 5 indexed citations
4.
Lev, Avital, Amriti R. Lulla, Brian C. Ross, et al.. (2018). ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer. Molecular Cancer Research. 16(5). 754–766. 22 indexed citations
5.
Lulla, Amriti R., Michael Slifker, Yan Zhou, et al.. (2017). miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells. Cancer Research. 77(24). 6902–6913. 44 indexed citations
6.
Ralff, Marie D., C. Leah B. Kline, Jessica Wagner, et al.. (2017). ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms. Molecular Cancer Therapeutics. 16(7). 1290–1298. 38 indexed citations
7.
Prabhu, Varun V., Bo Hong, Joshua E. Allen, et al.. (2016). Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation. Cancer Research. 76(7). 1989–1999. 49 indexed citations
8.
Abdulghani, Junaid, Jean‐Nicolas Gallant, David T. Dicker, et al.. (2016). Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC). Clinical Cancer Research. 22(24). 6192–6203. 35 indexed citations
9.
Zhang, Shengliang, Lanlan Zhou, Bo Hong, et al.. (2015). Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53. Cancer Research. 75(18). 3842–3852. 92 indexed citations
10.
Allen, Joshua E., Varun V. Prabhu, Mala K. Talekar, et al.. (2015). Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Research. 75(8). 1668–1674. 35 indexed citations
11.
Hao, Sijie, Shuwen Wang, Yuanjun Zhao, et al.. (2015). A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus. Molecular Cancer Therapeutics. 14(3). 835–843. 18 indexed citations
12.
Prabhu, Varun V., Joshua E. Allen, David T. Dicker, & Wafik S. El‐Deiry. (2015). Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem–like Cells in an Akt/Foxo3a/TRAIL–Dependent Manner. Cancer Research. 75(7). 1423–1432. 113 indexed citations
13.
Patel, Akshal, Varun V. Prabhu, David T. Dicker, et al.. (2014). COX-2 Drives Metastatic Breast Cells from Brain Lesions into the Cerebrospinal Fluid and Systemic Circulation. Cancer Research. 74(9). 2385–2390. 15 indexed citations
14.
Hong, Bo, Varun V. Prabhu, Shengliang Zhang, et al.. (2013). Prodigiosin Rescues Deficient p53 Signaling and Antitumor Effects via Upregulating p73 and Disrupting Its Interaction with Mutant p53. Cancer Research. 74(4). 1153–1165. 69 indexed citations
15.
Allen, Joshua E., Roger Ferrini, David T. Dicker, et al.. (2012). Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes. Molecular Cancer Therapeutics. 11(10). 2087–2095. 25 indexed citations
16.
Dolloff, Nathan G., Joshua E. Allen, David T. Dicker, et al.. (2012). Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9. Molecular Cancer Therapeutics. 11(11). 2321–2330. 12 indexed citations
17.
Mayes, Patrick A., Nathan G. Dolloff, Colin J. Daniel, et al.. (2011). Overcoming Hypoxia-Induced Apoptotic Resistance through Combinatorial Inhibition of GSK-3β and CDK1. Cancer Research. 71(15). 5265–5275. 27 indexed citations
18.
Laguinge, Luciana M., Raed Samara, Wenge Wang, et al.. (2008). DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines. Cancer Research. 68(3). 909–917. 40 indexed citations
19.
Plastaras, John P., Seok-Hyun Kim, Yingqiu Y. Liu, et al.. (2007). Cell Cycle–Dependent and Schedule-Dependent Antitumor Effects of Sorafenib Combined with Radiation. Cancer Research. 67(19). 9443–9454. 118 indexed citations
20.
Kim, Seok‐Hyun, Hiroshi Nakagawa, Arunasalam Navaraj, et al.. (2006). Tumorigenic Conversion of Primary Human Esophageal Epithelial Cells Using Oncogene Combinations in the Absence of Exogenous Ras. Cancer Research. 66(21). 10415–10424. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen H. Vousden Breakdown of academic impact, for papers by Moshe Oren Breakdown of academic impact, for papers by David P. Lane Breakdown of academic impact, for papers by Scott W. Lowe Breakdown of academic impact, for papers by Michael B. Kastan Breakdown of academic impact, for papers by Kornélia Polyák Breakdown of academic impact, for papers by William C. Hahn Breakdown of academic impact, for papers by Victor E. Velculescu Breakdown of academic impact, for papers by David A. Tuveson Breakdown of academic impact, for papers by Albert J. Fornace
Rankless by CCL
2026